MDM2-BCL-XL PROTACs enable degradation of BCL-XL and stabilization of p53
Inhibition or degradation of the anti-apoptotic protein BCL-XL is a viable strategy for cancer treatment. Despite the recent development of PROTACs for degradation of BCL-XL, the choice of E3 ligase has been restricted to VHL and CRBN. Herein, we report the development of MDM2-BCL-XL PROTACs using M...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book |
| Published: |
Compuscript Ltd,
2022-08-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|